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ABSTRACT 
Corporate social responsibility (CSR) is essential for both the society and more so, 
specifically the pharmaceutical industry. Companies now measure success in multiple ways beyond 
just profits, such as benefits to society. This is the “triple bottom line” approach, it takes into account 
stakeholders in addition to shareholders. Businesses are now seeing the long-term value of giving 
back to the society in which they conduct business. Sustaining health in various communities can raise 
the standard of living, increasing paying customers and instilling brand loyalty. In addition, there is 
evidence that mitigating negative public perception can relieve some of the excessive regulation that is 
now in place. Within this context, I provide real-world examples of CSR programs that pharmaceutical 
companies are currently engaged in and show how these programs help both society and the 
pharmaceutical industry itself. In closing, I discuss opportunities for the pharmaceutical industry’s 
current CSR initiatives. 
 




In conducting business operations, business people should not only pursue profits, 
but also expect to contribute positively to the social environment. This is because people 
have become more critical and capable of social control over the business. This strategy 
business is known as corporate social responsibility (CSR). The term CSR was founded for 
the first time in the writings of Social Responsibility of the Businessman in 1953 (Bowen, 
1953). Howard Rothman Bowen revealed that the presence of CSR is not obliged by the 
government or authority, but rather a commitment that was born in the context of business 
ethics (beyond legal aspects) in order to prosper as a society based on the principle of merit 
as the value and needs of the community. 
Nowadays, corporations have become more responsible by focusing on activities 
that benefit the community, such as considering the environment, sponsoring students for 
higher education, product quality, safety and so on. Corporate social responsibility (CSR) is 
regarded as a means by which firms improve their image and maintain their license to 
operate. Indeed, it can be viewed as a promotional campaign to enhance corporate 
regulations and public relations (KPMG, 2005). CSR disclosure is indicated in the literature 
as increasing competitive advantage (Bansal and Roth, 2000). It is defined as open and 
transparent business practices that are based on ethical values and respect for the community, 
employees, environment, shareholders and their stakeholders (Bowen 1953). It is certainly 
beneficial to the presence of CSR disclosure will have an impact, either directly or indirectly 
to corporate finance in the future. Investors also want their investment and confidence in the 
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company to have a good image in the public. Thus, if companies do CSR programs as an 
ongoing basis, the company will be able to run well. Therefore, the CSR program is more 
appropriate to be classified as an investment and should be the business strategy of the 
company (Bansal and Roth, 2000). 
In accounting, there is also a concept of social accounting as a part of the knowledge 
of accounting and report that aims to measure the social effects (social costs and benefits) 
arising from the business unit's activities (McNamara, 1999). Hence the company has a 
broader responsibility to make money not only for shareholders, but also for all stakeholders. 
Company in this case is an economic entity that is responsible not only to shareholders but 
also to the wider community. In accordance to social accounting, the annual financial report 
is one tool that can be used for the disclosure of social and environmental information. In 
addition, the economic decision made by looking at a company's financial performance, now 
is no longer relevant. Eipstein and Freedman (1994) found that individual investors are 
attracted to social information reported in the annual report. Therefore, a tool that can 
provide information about the social, environmental and financial aspect is needed. This 
report then is known as sustainability report. Specifically, sustainability report is used to 
report on economic policy, environmental and social impact and performance of the 
organization and its products in the context of sustainable development. Sustainability report 
includes the report on economic, environmental and social influences in relation to 
organizational performance. 
However, most companies face various challenges of the external environment 
which are often difficult or dilemmatic to response. Poor governance is one of main 
obstacles that discouraged companies to invest in Indonesia. Corruption is a pervasive 
problem affecting the health sector, with wide negative effects on health status and social 
welfare. In this context, the pharmaceutical companies have an important role for a 
generalized recovery of effectiveness in the health sector, taking into account: the global 
action of these companies; the frequent and relevant relationships with all operators in the 
sector, with relations that typically exclude the end user of the service; the crucial role in the 
prevention of incorrect behaviors; the promotion of an ethical culture and sustainability in 
healthcare (Bansal and Roth, 2000). 
A company oriented to sustainable development is clearly aware of its 
responsibilities towards the various stakeholders and adopts methods and tools of governance 
that will improve its economic, social and ecological performance. We are talking about an 
approach based on a broad vision of responsibility, on a modern interpretation of the links 
between the long-term success and the equitable resolution of the interests of all stakeholders 
(Bansal and Roth, 2000). Pharmaceutical companies must therefore be geared to the 
integration of economic goals and socio-ecological one, emphasizing the interdependence of 
economic, social and environmental responsibility in order to the optimization of the results 
compared to stakeholders‘ expectations. 
The increasing emphasis on the affirmation of governance oriented to global 
responsibility and the stakeholder relationship management, involves a greater accentuation 
on principles and values of the dominant internal and external relations, as well as the 
innovation of processes designed to ensure a systematic, coordinated, effective and efficient 
approach for the sustainable development. 
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In this sense, international recommendations and national rules have recently proliferated 
promoting an increasing emphasis on tools and management processes oriented to the 
improvement of corporate responsibility. In fact, the concepts of sustainable development 
and corporate social responsibility (CSR) are strictly interrelated. Based on the background 
issues that have been described above, generally the purpose of the current research is to 
compare and examine the difference of CSR disclosure in the pharmaceutical industry in 
Indonesia and Australia. The firms examined are listed in the Indonesian Stock Exchange 
(IDX) and Australian Stock Exchange (ASX). Specifically, the annual report the firms 
published for year 2016. The research uses International Standard ISO 26000  on  Guidance  
on  Social  Responsibility  as  a  measure  of  CSR  disclosure,  with the indicators taken 
from the one of the seven core of ISO 26000 Sustainability Reporting. Specifically, on Fair 
Operating Practices. 
The results of the paper, which will be discussed later on, imply the need to develop 
better CSR disclosure as well as its appropriate measures within corporations in Indonesia. 
Besides, this condition may become the consideration for regulatory body to take more 
action to ensure the integrity of corporate social responsibility, especially awareness of the 
importance of CSR and its disclosure in annual report. Moreover, this research implies that 
there are many companies in Indonesian that have been engaged to corporate social 
responsibility, although the disclosure has not been sufficient. It comes to be the evidence for 
internal and external parties that it needs further consideration and should not solely rely on 
financial numbers listed on financial statement to take an investment and management 
decision. On the other hand, it may also support corporate to be more aware with a corporate 
social responsibility. 
Finally, it is essential to integrate the CSR concept into accounting education 
because it‘s important to develop and improve to broaden the perspective the term of CSR in 
Indonesia. It is also important to enrich the research in accounting with studies related to 
CSR. This is because the research results are able to contribute to the literature to more 
widely explain the phenomenon of corporate social responsibility disclosure and its impact 
on financial performance. It is expected, by referring to this research, that the academics could 
develop new findings to solve the problem related to social responsibility which may impact 
the society. 
This paper is organized as follows. This first part has discussed the background as 
well as the contributions of the study. The next part will examine the literatures that have 
been written previously in relation to the connection between CSR disclosure and firm 
financial performance. The third part includes the research method applied. Finally, the 
paper will be summed up and the limitations found during the study are described on the last 
section. 
CORPORATE SOCIAL RESPONSIBILITY DISCLOSURE 
Corporate Social Responsibility (CSR) can be defined as a company‘s voluntary 
contribution to sustainable development which goes beyond legal requirements (Bowen 
1953). Under the current ‗‗profit-maximizing CSR perspective,‘‘ firms have to consider the 
social and environmental costs and benefits to maximize their value (Bowen 1953). That is, 
companies are assumed to be socially responsible because they anticipate benefiting from 
these actions. Examples of such benefits might include the ability to charge a premium price 
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for its output or the use of CSR to recruit and retain high quality workers. These benefits are 
presumed to offset the higher costs associated with CSR, since resources must be allocated to 
allow the firm to achieve a higher CSR status. 
The growing CSR awareness is also reflected in the increasing number of CSR and 
sustainability reports, as well as in the provision of CSR-related information (Gray et al. 
2001). Corporate social responsibility disclosure (CSRD) can be defined as the information 
that a company discloses about its environmental impact and its relationship with its 
stakeholders by means of relevant communication channels. Many different theoretical 
attempts have been made to explain why companies voluntarily disclose CSR information 
(Dowling and Pfeffer 1975). We rely on political cost theory to develop our hypotheses. The 
political cost theory suggests that managers are concerned with political considerations, 
including preventing explicit or implicit taxes, or other regulatory actions (Healy and Palepu 
2001; Watts and Zimmermann 1978). In addition to politicians, non-governmental interest 
groups and other stakeholders increasingly try to influence companies‘ actions to favor their 
specific interests. They thus have the power to affect wealth transfers between the company 
and other stakeholders. Our assumption is that by disclosing information on their social and 
environmental performance, firms want to minimize the (potential) costs arising from the 
interaction between the firm and its natural and societal environment—referred to as political 
or societal costs. 
Companies can employ a number of methods to reduce the likelihood of 
adverse political or societal actions and the resulting costs (Watts and Zimmermann 1978). 
One of them is to disclose CSR information, as this allows the firm to generate moral 
capital that, for example, can temper punitive sanctions in the case of a negative event 
(Godfrey 2005). Empirical evidence seems to confirm this notion. For instance, Lyon and 
Maxwell (2006, 2007) find that firms with poor reputations disclose fully, while firms 
with excellent reputations disclose nothing, as they gain little by disclosing successes since 
they are expected to succeed. 
 
INTERNATIONAL STANDARD ISO 26000 SUSTAINABILITY REPORTING 
Organizations around the world, and their stakeholders, are becoming increasingly 
aware of the need for and benefits of socially responsible behavior. The objective of social 
responsibility is to contribute to sustainable development. 
An organization's performance in relation to the society in which it operates and to 
its impact on the environment has become a critical part of measuring its overall performance 
and its ability to continue operating effectively. This is, in part, a reflection of the growing 
recognition of the need to ensure healthy ecosystems, social equity and good organizational 
governance. In the long run, all organizations' activities depend on the health of the world's 
ecosystems. Organizations are subject to greater scrutiny by their various stakeholders. The 
perception and reality of an organization's performance on social responsibility can 
influence, among other things: its competitive advantage, its reputation, its ability to attract 
and retain workers or members, customers, clients or users, the maintenance of employees' 
morale, commitment and productivity, the view of investors, owners, donors, sponsors and the 
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financial community and its relationship with companies, governments, the media, suppliers, 
peers, customers and the community in which it operates. 
ISO 26000 – FAIR OPERATING PRACTICES 
Fair operating practices concern ethical conduct in an organization's dealings with 
other organizations. These include relationships between organizations and government 
agencies, as well as between organizations and their partners, suppliers, contractors, 
customers, competitors, and the associations of which they are members.  
Fair operating practice issues arise in the areas of anti-corruption, responsible 
involvement in the public sphere, fair competition, socially responsible behavior, relations 
with other organizations and respect for property rights. 
In the area of social responsibility, fair operating practices concern the way an 
organization uses its relationships with other organizations to promote positive outcomes. 
Positive outcomes can be achieved by providing leadership and promoting the adoption of 
social responsibility more broadly throughout the organization's sphere of influence. 
FAIR OPERATING PRACTICES: ANTI-CORRUPTION 
Corruption is the abuse of entrusted power for private gain. Corruption can take 
many forms. Examples of corruption include bribery (soliciting, offering or accepting a bribe 
in money or in kind) involving public officials or people in the private sector, conflict of 
interest, fraud, money laundering, embezzlement, concealment and obstruction of justice, 
and trading in influence. 
Corruption undermines an organization's effectiveness and ethical reputation, and 
can make it liable to criminal prosecution, as well as civil and administrative sanctions. 
Corruption can result in the violation of human rights, the erosion of political processes, 
impoverishment of societies and damage to the environment. It can also distort competition, 
distribution of wealth and economic growth. 
 
FAIR OPERATING PRACTICES: RESPONSIBLE POLITICAL INVOLVEMENT 
Organizations can support public political processes and encourage the development 
of public policy that benefits society at large. Organizations should prohibit use of undue 
influence and avoid behavior, such as manipulation, intimidation and coercion, that can 
undermine the public political process. 
 
FAIR OPERATING PRACTICES: FAIR COMPETITION 
Fair and widespread competition stimulates innovation and efficiency, reduces the 
costs of products and services, ensures all organizations have equal opportunities, 
encourages the development of new or improved products or processes and, in the long run, 
enhances economic growth and living standards. Anti-competitive behavior risks harming the 
reputation of an organization with its stakeholders and may create legal problems. When 
organizations refuse to engage in anti-competitive behavior they help to build a climate in 
which such behavior is not tolerated, and this benefit everyone. 
There are many forms of anti-competitive behavior. Some examples are: price fixing, where 
parties collude to sell the same product or service at the same price; bid rigging, where 
parties collude to manipulate a competitive bid; and predatory pricing, which is selling a 
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product or service at a very low price with the intent of driving competitors out of the market 
and imposing unfair sanctions on competitors. 
 
FAIR OPERATING PRACTICES: PROMOTING SOCIAL 
RESPONSIBILITY IN THE VALUE CHAIN 
An organization can influence other organizations through its procurement and 
purchasing decisions. Through leadership and mentorship along the value chain, it can 
promote adoption and support of the principles and practices of social responsibility. 
An organization should consider the potential impacts or unintended consequences 
of its procurement and purchasing decisions on other organizations, and take due care to 
avoid or minimize any negative impacts. It can also stimulate demand for socially 
responsible products and services. These actions should not be viewed as replacing the role 
of authorities to implement and enforce laws and regulations. 
FAIR OPERATING PRACTICES: RESPECT FOR PROPERTY RIGHTS 
The right to own property is a human right recognized in the Universal Declaration 
of Human Rights. Property rights cover both physical property and intellectual property and 
include interest in land and other physical assets, copyrights, patents, geographical indicator 
rights, funds, moral rights and other rights. They may also encompass a consideration of 
broader property claims, such as traditional knowledge of specific groups, such as 
indigenous peoples, or the intellectual property of employees or others. 
Recognition of property rights promotes investment and economic and physical 
security, as well as encouraging creativity and innovation. 
Table 1 





















identify the risks of corruption and implement and maintain 




ensure its leadership sets an example for anti-corruption and 
provides commitment, encouragement and oversight for 
implementation of the anti-corruption policies 
 
FOP3 
support and train its employees and representatives in their 
efforts to eradicate bribery and corruption, and provide 
incentives for progress 
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raise the awareness of its employees, representatives, 




ensure that the remuneration of its employees and 
representatives is appropriate and for legitimate services only 
 





encourage its employees, partners, representatives and 
suppliers to report violations of the organization's policies and 
unethical and unfair treatment by adopting mechanisms that 
enable reporting and follow-up action without fear of reprisal 
FOP8 
bring violations of the criminal law to the attention of 
appropriate law enforcement authorities 
 
FOP9 
work to oppose corruption by encouraging others with which the 





train its employees and representatives and raise their awareness 
regarding responsible political involvement and contributions, 
and how to deal with conflicts of interest 
 
FOP11 
be transparent regarding its policies and activities related to 
lobbying, political contributions and political involvement 
 
FOP12 
establish and implement policies and guidelines to manage the 





avoid political contributions that amount to an attempt to control 
or could be perceived as exerting undue influence on politicians 
or policymakers in favour of specific causes 
FOP14 
prohibit activities that involve misinformation, 
misrepresentation, threat or compulsion 
 
FOP15 
conduct its activities in a manner consistent with competition 
laws and regulations, and co-operate with the appropriate 
authorities 
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establish procedures and other safeguards to prevent engaging in 
or being complicit in anti-competitive behaviour 
 
FOP17 
promote employee awareness of the importance of compliance 
with competition legislation and fair competition 
FOP18 
upport anti-trust and anti-dumping practices, as well as public 
policies that encourage competition 
 
FOP19 
be mindful of the social context in which it operates and not take 




integrate ethical, social, environmental and gender equality 
criteria, and health and safety, in its purchasing, distribution and 
contracting policies and practices to improve consistency with 
social responsibility objectives 
 
FOP21 
encourage other organizations to adopt similar policies, without 




carry out appropriate due diligence and monitoring of the 
organizations with which it has relationships, with a view to 




consider providing support to SMOs, including awareness 




actively participate in raising the awareness of organizations 




promote fair and practical treatment of the costs and benefits of 
implementing socially responsible practices throughout the value 
chain, including, where possible, enhancing the capacity of 
organizations in the value chain to meet socially responsible 
objectives. This includes adequate purchasing practices, such as 
ensuring that fair prices are paid and that there are adequate 
delivery times and stable contracts 
FOP26 
implement policies and practic s that promote r pect for
property rights nd traditional knowledge 
FOP27 
conduct proper investigations to be confident it has lawful title 
permitting use or disposal of property 
FOP28 
not engage in activities that violate property rights, including 
misuse of a dominant position, counterfeiting and piracy 
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FOP29 pay fair compensation for property that it acquires or uses 
 
FOP30 
consider the expectations of society, human rights and basic 
needs of the individual when exercising and protecting its 
intellectual and physical property rights. 
 
SAMPLE CONSTRUCTION 
The study population is all pharmaceutical firms listed on the Indonesian Stock 
Exchange (IDX) and Australian Stock Exchange (ASX) during 2016. From the population 
firms in IDX and ASX, two firms from IDX and two firms from ASX are selected by 
random as sample. To ensure the firm selected is chosen at random and free from bias, the 
researcher list the population, assign number to the population, and then a random number 
generator program is used to ensure randomness. 
 
CONTENT ANALYSIS 
In this analysis, we are interested in the CSR information (message) transmitted by 
corporate reports (communication channel) and provided by the sample companies (source) 
to their stakeholders. Similar to previous studies, we use content analysis to quantify the 
amount of CSR information in the reports. We apply a so-called ‗‗third party approach‘‘ in 
which content analysis is carried out by someone who is neither a provider (source) nor a 
receiver of the report. 
A disclosure index (see Table 1) is used (similar to other studies conducted in this 
area of accounting research) to provide an evaluation of the CSR disclosure based on sample 
firm‘s annual reports. Consistent with other studies (Aly & Simon 2008; Desoky 2009), an 
un- weighted disclosure index, which treats all items equally with a dichotomous procedure 
in which an item scores (1) if it is disclosed and (0) otherwise, was adopted in this study, 
implying that all items are equal in importance. 
This approach, based on un-weighted items, has become the norm in disclosure 
studies because it reduces subjectivity (Ahmed & Courtis 1999). The first step in applying 
this approach is the selection of items of CSR information that could be disclosed in 
companies‘ web-sites, including a soft copy of the company‘s annual reports. Because there is 
no generally agreed upon accepted model for the selection of items of CSR information to be 
included in a disclosure index, the researchers based the selection of disclosure items on an 
extensive review of the relevant literature (Hossain et. Al 2006; Hassan et. Al 2012). 
DISCLOSURE INDEX SCORE 
Table 2 








KLBF KAEF CSL SRX 
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identify the risks of corruption 
and implement and maintain 
policies and practices that 


















ensure its leadership sets an 
example for anti corruption 
and provides commitment, 
encouragement and oversight for 
implementation of the anti- 
corruption policies 
1 1 1 1 
 
FOP3 
support and train its employees and 
representatives in their efforts to 
eradicate bribery and corruption, 










raise the awareness of its 
employees, representatives, 
contractors and suppliers about 










ensure that the remuneration of its 
employees and representatives is 











establish and maintain an effective 











encourage its employees, partners, 
representatives and suppliers to 
report violations of the 
organization's policies and 
unethical and unfair treatment by 
adopting mechanisms that enable 
reporting and follow-up action 











bring violations of the criminal law 
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work to oppose corruption by 
encouraging others with which the 
organization has operating 
relationships to adopt similar anti-
corruption practices 
 































train its employees and 
representatives and raise their 
awareness regarding 
responsible political 
involvement and contributions, and 












be transparent regarding its 
policies and activities related to 
lobbying, political 












establish and implement policies 
and guidelines to manage the 
activities of people retained to 














avoid political contributions that 
amount to an attempt to control or 
could be perceived as exerting 
undue influence on politicians or 





















prohibit activities that involve 
misinformation,misrepresentation, 





























conduct its activities in a manner 
consistent with competition laws 
and regulations, and co-operate 




















establish procedures and other 
safeguards to prevent engaging in 

















promote employee awareness of 
the importance of compliance with 
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support anti-trust and anti- 
dumping practices, as well as 
public policies that encourage 
competition 





be mindful of the social context in 
which it operates and not take 
advantage of social conditions, 
























integrate ethical, social, 
environmental and gender equality 
criteria, and health and safety, in 
its purchasing, distribution and 
contracting policies and practices 











encourage other organizations to 
adopt similar policies, without 
indulging in anti- competitive 
behaviour in so doing 
0 0 0 1 
 
FOP22 
carry out appropriate due diligence 
and monitoring of the 
organizations with which it has 
relationships, with a view to 
preventing compromise of the 















consider providing support to 
SMOs, including awareness raising 
on issues of social responsibility 












actively participate in raising the 
awareness of organizations with 
which it has relationships about 
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promote fair and practical 
treatment of the costs and benefits 
of implementing socially 
responsible practices throughout 
the value chain, including, where 
possible, enhancing the capacity of 
organizations in the value chain to 
meet socially responsible 
objectives. This includes adequate 
purchasing practices, such as 
ensuring that fair prices are   paid   
and   that   there are 



























implement policies and practices 
that promote respect for property 















conduct proper investigations to be 
confident it has lawful title 
















not engage in activities that violate 
property rights, including misuse 
of a dominant position, 









pay fair compensation for 
property that it acquires or uses 
1 0 0 0 
 
FOP30 
consider the expectations of 
society, human rights and basic 
needs of the individual when 
exercising and protecting its 









Index Score 25 12 16 15 
Index Conformity Score 0.83 0.40 0.53 0.50 
 
SUMMARY 
The objective of this study is to evaluate the level of CSR disclosure based on 
International Standard ISO 26000 Sustainability Reporting for pharmaceutical firms in the 
IDX and ASX. To achieve these objectives, a disclosure index incorporating 30 items of 
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CSR information was applied to the annual reports of two pharmaceutical firms in IDX and 
two pharmaceutical firms in ASX. The reason the result varies significantly between the two 
countries is because of the difference in the sustainability reporting standard. In Australia, 
companies usually have another report called the sustainability report that specifically 
explains their sustainability and CSR effort, thus exclude most of their sustainability and 
CSR effort in their annual report while in Indonesia, this distinction doesn‘t exist. 
The current study has a number of limitations. First, the findings of such a study 
may not be generalized to different countries at different stages of development or with 
different business environments and cultures. Second, while an un-weighted disclosure 
index was used in this study, the findings might be different if a weighted disclosure index 
which assesses the importance of each item in accordance with specific user group‘ 
perspective were used. Third, Future study may be needed to investigate the impact of other 
potential explanatory variables such as those related to corporate governance which are not 
included in this research. 
To formulate a more robust conclusion it would be necessary to increase the 
company sample. Another limitation refers to the fact that the study does not address 
possible cross- country differences in the characteristics of corporate disclosure, assuming 
that GRI guidelines represent a standard that has set the tone and language for economic, 
social and environmental communication worldwide. Lastly, the empirical analysis does not 
consider other factors – such as management turnover – that might have an impact on 
company disclosure apart from industrial disaster. These additional factors that may cause a 
change in disclosure are considered to be irrelevant since the final aim of this paper is to 
contrast results. 
Future research should also try to apply more advanced text mining instruments like 
natural language processing in order to verify if combinations of words – which are closer to 
human language – lead to results that are more similar to those obtained from content 
analysis. Thanks to continuous advancements in technology, text mining is becoming more 
and more sophisticated and may become a substitute for content analysis in the near future 
when researchers need to detect patterns in textual data and quantify the relevance of certain 
themes. 
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